Company / Operating Income
LENZ Therapeutics, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$91.1M
FY2025
5-year range
-$105.6M / -$58.6M
FY2021-FY2025
Trend
-55.5%
vs FY2024
Sector context
#87 of 204
Health Care
What the data says
At -$91M, LENZ Therapeutics, Inc.'s operating income ranks #87 of 204 in the Health Care sector. Declined from -$72M to -$91M over the past 2 years.
Based on SEC 10-K filings.
-$91M in FY2025.
Declined from -$72M to -$91M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#87 of 204 in Health CareTop 43% of 204This company -$91.1M Sector average $107.7M
▼
-184.6% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 55.5% year-over-year.
- Ranks #87 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$91.1M | -55.5% |
| FY2024 | -$58.6M | +19.1% |
| FY2023 | -$72.4M | +31.4% |
| FY2022 | -$105.6M | -74.8% |
| FY2021 | -$60.4M | -347.7% |
| FY2020 | -$13.5M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026